Billionaires Holding MGNX

BILLIONAIRE ALLOCATION SHARES OWNED (M) % CO AVG. COST RETURN

FUNDAMENTALS

  • N/A
    PE

  • 0.0
    Yield

  • 34.2M
    Shares Outstanding

  • 995.59M
    Market Cap

News & Insights

ABOUT

MGNX

MacroGenics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The company generates its pipeline of product candidates from its propr...

Google parent Alphabet's earnings: $8.42 per share, vs expected EPS of $8.04

NEWS

Amazon keeps its crown as king of cloud as sales pop

READ MORE